Atheneos Capital
4701 Patrick Henry Drive Great America Technology Park Building 25, No. 1909, Santa Clara, CA, 95054, United States
Overview
Atheneos Ventures is an evergreen fund that provides funding to early-stage companies rooted in the life sciences industry. It is a San Francisco Bay Area-based, healthcare-focused, evergreen fund dedicated to identifying and nurturing high quality, high risk (and potentially) game-changing healthcare companies. Previously specializing in common diseases, Atheneos Ventures forges ahead focusing on orphan drugs and rare diseases.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Venture Capital
Investment portfolio
- Armetheon
Participated · Series A · Aug 2014
Armetheon is a San Francisco Bay area clinical-stage specialty biopharmaceutical company focused on cardiovascular disease. Its lead candidate, tecarfarin, is a novel vitamin-K-antagonist (VKA) oral anticoagulant designed to avoid adverse drug reactions associated with warfarin. The company intends to use the Series B proceeds to advance tecarfarin through pivotal clinical development. Tecarfarin’s final pivotal study (TACT) is a 3,000-patient, open-label, real-world trial conducted under a Special Protocol Assessment agreed with the FDA in April 2014. The TACT trial will compare tecarfarin with warfarin across indications requiring oral anticoagulation, including underserved populations such as patients who respond poorly to warfarin and patients with prosthetic heart valves. The company is led by M. (Ken) Kengatharan, Ph.D., President and Interim CEO. Armetheon develops mid- to late-stage cardiovascular drug candidates with a focus on oral anticoagulation and atrial fibrillation. Its lead program is Tecarfarin, which is being investigated for all patients who require an oral anticoagulant, including those with mechanical heart valves. Earlier in the year the company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for the final pivotal trial, TACT, for Tecarfarin. The company raised $7.0m in a Series A financing to support its programs and to keep an NDA filing timeline in 2017 for Tecarfarin. Armetheon was founded in 2011 by M. (Ken) Kengatharan, PhD, who serves as President & COO. The company is based in the San Francisco Bay area.
- Altheos
Participated · Series A · Apr 2010
Altheos is an early-stage biopharmaceutical company based in South San Francisco focused on identifying and developing small-molecule drugs for unmet medical needs. The company's lead program is ATS907, a selective Rho-kinase inhibitor licensed from Asahi Kasei Pharma. The license also includes the AK138 series of highly active compounds intended for topical treatment of glaucoma. Altheos completed a $20M Series A financing to fund its development programs. The new capital will be used primarily for development of ATS907. In conjunction with the financing the company expanded its board, adding Lester Kaplan as chairman and appointing Rob Hopfner (Bay City Capital), Peter Bisgaard (Novo A/S) and Wende Hutton (Canaan Partners).
Team
No current team members are available.